SEARCH

SEARCH BY CITATION

References

  • 1
    Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004; 25: 399404.
  • 2
    Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Cancer Biol 2000; 10: 41533.
  • 3
    O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 2006; 42: 25767.
  • 4
    Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 355060.
  • 5
    Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas. Eur J Haematol 2003; 71: 919.
  • 6
    Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO. Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 9981004.
  • 7
    Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 82739.
  • 8
    Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 355060.
  • 9
    Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004; 130: 3744.
  • 10
    Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005; 83: 28797.
  • 11
    Kossakowska AE, Hinek A, Edwards DR, Lim MS, Zhang CL, Breitman DR, Prusinkiewicz C, Stabbler AL, Urbanski LS, Urbanski SJ. Proteolytic activity of human non-Hodgkin's lymphomas. Am J Pathol 1998; 152: 56576.
  • 12
    Kossakowska AE, Urbanski SJ, Janowska-Wieczorek A. Matrix metalloproteinases and their tissue inhibitors—expression, role and regulation in human malignant non-Hodgkin's lymphomas. Leuk Lymphoma 2000; 39: 48593.
  • 13
    Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol 2008; 80: 4654.
  • 14
    Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999; 107: 1119.
  • 15
    Bode W, Fernandez-Catalan C, Grams F, Gomis-Rüth FX, Nagase H, Tschesche H, Maskos K. Insights into MMP-TIMP interactions. Ann NY Acad Sci 1999; 878: 7391.
  • 16
    Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001; 61: 34507.
  • 17
    Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Jr., Kallakury BV. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003; 16: 198205.
  • 18
    Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 1996; 224: 1105.
  • 19
    Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 24653.
  • 20
    Lim MS, Guedez L, Stetler-Stevenson WG, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann NY Acad Sci 1999; 878: 5223.
  • 21
    DeClerck YA, Darville MI, Eeckhout Y, Rousseau GG. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994; 139: 18591.
  • 22
    Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 754958.
  • 23
    Vasku A, Tschoplova S, Izakovicova Holla L, Semradova V, Vacha J. Genotype association of C(−735)T polymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 2002; 204: 2625.
  • 24
    Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64: 76228.
  • 25
    Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW, Patsouris E. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 2007; 17: 9638.
  • 26
    Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2007; 25: 399404.
  • 27
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 136192.
  • 28
    WHO. World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues, 3rd ed. Lyon: IARC Press; 2001.
  • 29
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
  • 30
    Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 2002; 63: 398790.
  • 31
    Kang S, Zhao X, Xing H, Wang N, Zhou R, Chen S, Li W, Zhao J, Duan Y, Sun D, Li Y. Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis. Environ Mol Mutagen 2008; 49: 22631.
  • 32
    Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004; 25: 399404.
  • 33
    Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004; 64: 76228.
  • 34
    Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005; 26: 111721.
  • 35
    Rollin J, Régina S, Vourc'h P, Iochmann S, Bléchet C, Reverdiau P, Gruel Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007; 56: 27380.
  • 36
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002; 8: 38203.
  • 37
    Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, Day I, Howell WM. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res 2001; 61: 12968.
  • 38
    Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human epithelial cells. Cancer Res 1999; 59: 626775.
  • 39
    Jiang Y, Wang M, Celiker MY, Liu YE, Sang QX, Goldberg ID, Shi YE. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of metalloproteinase 4 gene delivery. Cancer Res 2001; 61: 236570.
  • 40
    Diao LP, Yu XM, Gao YH, Li Y, Liu HS, Liu LH, Zhou RM, Wang N, Wu LL, Wang SJ. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 2009; 135: 147381.